A service of StreetInsider.com
Ticker Symbol

Most Popular

AAPL 102.50
GOOG 571.60
MSFT 45.43
BAC 16.09
FB 74.82

Recently Added

SIAF 0.40
VOIL 1.16
UDHI 0.04
REVI 0.02
SOPW 0.72

Gaining Speed

APDN 0.11
REVI 0.02
UDHI 0.04
VOIL 1.16
SIAF 0.40

ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS....

Read More




Get Alerted When News Hits On This Stock - FREE!